Our data demonstrate the significance of the tumor-intrinsic STING-IFN-I signaling axis in the hDT806-induced tumor growth inhibition, and provide valuable insights into the development of novel immunotherapeutic approaches for treating HNSCC. This evidence concerns the gene STING1 and neoplasm.